Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19
This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non‐randomized controlled trial included 62 patients on the triple combination treatment versus 51 age‐...
Gespeichert in:
| Veröffentlicht in: | Journal of medical virology 2021-05, Vol.93 (5), p.3176-3183 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3183 |
|---|---|
| container_issue | 5 |
| container_start_page | 3176 |
| container_title | Journal of medical virology |
| container_volume | 93 |
| creator | Elalfy, Hatem Besheer, Tarek El‐Mesery, Ahmed El‐Gilany, Abdel‐Hady Soliman, Mahmoud Abdel‐Aziz Alhawarey, Ahmed Alegezy, Mohamed Elhadidy, Tamer Hewidy, Asem A. Zaghloul, Hossam Neamatallah, Mustafa Ahmed Mohamed Raafat, Douaa El‐Emshaty, Wafaa M. Abo El Kheir, Nermin Y. El‐Bendary, Mahmoud |
| description | This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non‐randomized controlled trial included 62 patients on the triple combination treatment versus 51 age‐ and sex‐matched patients on routine supportive treatment. all of them confirmed cases by positive reverse‐transcription polymerase chain reaction of a nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% on the 7th day and 13.7% and 73.1% on the 15th day in the supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates on the 15th day are 13.7% and 88.7% in the supportive treatment and combined antiviral groups, respectively. This trial concluded by stating that the combined use of nitazoxanide, ribavirin, and ivermectin plus zinc supplement effectively cleared the SARS‐COV2 from the nasopharynx in a shorter time than symptomatic therapy. |
| doi_str_mv | 10.1002/jmv.26880 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8014583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2509224528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5370-faed8821c4ce47c597ebd5f2d29beceebe4c6444582e9e08401e334de83e0abd3</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi1ERYfCghdAlthQqZnajp1xNkjVUMqgXiQuXbCxHPuEepTYwUkGpqu-AFKfkSfBw5QKFqws2Z-_8-v8CD2jZEoJYYfLdjVlhZTkAZpQUhZZSWb0IZoQyousKKjYRY_7fkkIkSVjj9BunouSlIRO0I_jugYz4FBjjU1oK-f14ILfXHg36OvwXXtn4QBHV-mVi84fYO0tdiuIbfrpPO6ascfXzhvcj13XQAt-wC_Pjs4_TM_fLz7jfhjteh8n6XAF2DSgo_YGNiNa11g8v7hcvP55c0vLJ2in1k0PT-_OPfTpzfHH-dvs9OJkMT86zYzIZySrNVgpGTXcAJ8ZUc6gsqJmlpUVGIAKuCk450IyKIFITijkObcgcyC6svkeerX1dmPVgjUpcNSN6qJrdVyroJ3698W7K_UlrJRMKxUyT4IXd4IYvo7QD2oZxuhTZsUESUvmgslE7W8pE0PfR6jvJ1CiNs2p1Jz63Vxin_8d6Z78U1UCDrfAN9fA-v8m9e7scqv8BfzxpaI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509224528</pqid></control><display><type>article</type><title>Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Elalfy, Hatem ; Besheer, Tarek ; El‐Mesery, Ahmed ; El‐Gilany, Abdel‐Hady ; Soliman, Mahmoud Abdel‐Aziz ; Alhawarey, Ahmed ; Alegezy, Mohamed ; Elhadidy, Tamer ; Hewidy, Asem A. ; Zaghloul, Hossam ; Neamatallah, Mustafa Ahmed Mohamed ; Raafat, Douaa ; El‐Emshaty, Wafaa M. ; Abo El Kheir, Nermin Y. ; El‐Bendary, Mahmoud</creator><creatorcontrib>Elalfy, Hatem ; Besheer, Tarek ; El‐Mesery, Ahmed ; El‐Gilany, Abdel‐Hady ; Soliman, Mahmoud Abdel‐Aziz ; Alhawarey, Ahmed ; Alegezy, Mohamed ; Elhadidy, Tamer ; Hewidy, Asem A. ; Zaghloul, Hossam ; Neamatallah, Mustafa Ahmed Mohamed ; Raafat, Douaa ; El‐Emshaty, Wafaa M. ; Abo El Kheir, Nermin Y. ; El‐Bendary, Mahmoud</creatorcontrib><description>This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non‐randomized controlled trial included 62 patients on the triple combination treatment versus 51 age‐ and sex‐matched patients on routine supportive treatment. all of them confirmed cases by positive reverse‐transcription polymerase chain reaction of a nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% on the 7th day and 13.7% and 73.1% on the 15th day in the supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates on the 15th day are 13.7% and 88.7% in the supportive treatment and combined antiviral groups, respectively. This trial concluded by stating that the combined use of nitazoxanide, ribavirin, and ivermectin plus zinc supplement effectively cleared the SARS‐COV2 from the nasopharynx in a shorter time than symptomatic therapy.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.26880</identifier><identifier>PMID: 33590901</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject><![CDATA[Adult ; Antimetabolites - administration & dosage ; Antimetabolites - therapeutic use ; Antiparasitic Agents - administration & dosage ; Antiparasitic Agents - therapeutic use ; antiviral ; Antiviral drugs ; COVID-19 ; COVID-19 - drug therapy ; Female ; Humans ; Ivermectin ; Ivermectin - administration & dosage ; Ivermectin - therapeutic use ; Male ; mild cases ; Nasopharynx ; Nitro Compounds - administration & dosage ; Nitro Compounds - therapeutic use ; Polymerase chain reaction ; Ribavirin ; Ribavirin - administration & dosage ; Ribavirin - therapeutic use ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Thiazoles - administration & dosage ; Thiazoles - therapeutic use ; Trace Elements - administration & dosage ; Trace Elements - therapeutic use ; Virology ; Zinc ; Zinc - administration & dosage ; Zinc - therapeutic use]]></subject><ispartof>Journal of medical virology, 2021-05, Vol.93 (5), p.3176-3183</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5370-faed8821c4ce47c597ebd5f2d29beceebe4c6444582e9e08401e334de83e0abd3</citedby><cites>FETCH-LOGICAL-c5370-faed8821c4ce47c597ebd5f2d29beceebe4c6444582e9e08401e334de83e0abd3</cites><orcidid>0000-0002-5602-0989</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.26880$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.26880$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33590901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elalfy, Hatem</creatorcontrib><creatorcontrib>Besheer, Tarek</creatorcontrib><creatorcontrib>El‐Mesery, Ahmed</creatorcontrib><creatorcontrib>El‐Gilany, Abdel‐Hady</creatorcontrib><creatorcontrib>Soliman, Mahmoud Abdel‐Aziz</creatorcontrib><creatorcontrib>Alhawarey, Ahmed</creatorcontrib><creatorcontrib>Alegezy, Mohamed</creatorcontrib><creatorcontrib>Elhadidy, Tamer</creatorcontrib><creatorcontrib>Hewidy, Asem A.</creatorcontrib><creatorcontrib>Zaghloul, Hossam</creatorcontrib><creatorcontrib>Neamatallah, Mustafa Ahmed Mohamed</creatorcontrib><creatorcontrib>Raafat, Douaa</creatorcontrib><creatorcontrib>El‐Emshaty, Wafaa M.</creatorcontrib><creatorcontrib>Abo El Kheir, Nermin Y.</creatorcontrib><creatorcontrib>El‐Bendary, Mahmoud</creatorcontrib><title>Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non‐randomized controlled trial included 62 patients on the triple combination treatment versus 51 age‐ and sex‐matched patients on routine supportive treatment. all of them confirmed cases by positive reverse‐transcription polymerase chain reaction of a nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% on the 7th day and 13.7% and 73.1% on the 15th day in the supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates on the 15th day are 13.7% and 88.7% in the supportive treatment and combined antiviral groups, respectively. This trial concluded by stating that the combined use of nitazoxanide, ribavirin, and ivermectin plus zinc supplement effectively cleared the SARS‐COV2 from the nasopharynx in a shorter time than symptomatic therapy.</description><subject>Adult</subject><subject>Antimetabolites - administration & dosage</subject><subject>Antimetabolites - therapeutic use</subject><subject>Antiparasitic Agents - administration & dosage</subject><subject>Antiparasitic Agents - therapeutic use</subject><subject>antiviral</subject><subject>Antiviral drugs</subject><subject>COVID-19</subject><subject>COVID-19 - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Ivermectin</subject><subject>Ivermectin - administration & dosage</subject><subject>Ivermectin - therapeutic use</subject><subject>Male</subject><subject>mild cases</subject><subject>Nasopharynx</subject><subject>Nitro Compounds - administration & dosage</subject><subject>Nitro Compounds - therapeutic use</subject><subject>Polymerase chain reaction</subject><subject>Ribavirin</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Thiazoles - administration & dosage</subject><subject>Thiazoles - therapeutic use</subject><subject>Trace Elements - administration & dosage</subject><subject>Trace Elements - therapeutic use</subject><subject>Virology</subject><subject>Zinc</subject><subject>Zinc - administration & dosage</subject><subject>Zinc - therapeutic use</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi1ERYfCghdAlthQqZnajp1xNkjVUMqgXiQuXbCxHPuEepTYwUkGpqu-AFKfkSfBw5QKFqws2Z-_8-v8CD2jZEoJYYfLdjVlhZTkAZpQUhZZSWb0IZoQyousKKjYRY_7fkkIkSVjj9BunouSlIRO0I_jugYz4FBjjU1oK-f14ILfXHg36OvwXXtn4QBHV-mVi84fYO0tdiuIbfrpPO6ascfXzhvcj13XQAt-wC_Pjs4_TM_fLz7jfhjteh8n6XAF2DSgo_YGNiNa11g8v7hcvP55c0vLJ2in1k0PT-_OPfTpzfHH-dvs9OJkMT86zYzIZySrNVgpGTXcAJ8ZUc6gsqJmlpUVGIAKuCk450IyKIFITijkObcgcyC6svkeerX1dmPVgjUpcNSN6qJrdVyroJ3698W7K_UlrJRMKxUyT4IXd4IYvo7QD2oZxuhTZsUESUvmgslE7W8pE0PfR6jvJ1CiNs2p1Jz63Vxin_8d6Z78U1UCDrfAN9fA-v8m9e7scqv8BfzxpaI</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Elalfy, Hatem</creator><creator>Besheer, Tarek</creator><creator>El‐Mesery, Ahmed</creator><creator>El‐Gilany, Abdel‐Hady</creator><creator>Soliman, Mahmoud Abdel‐Aziz</creator><creator>Alhawarey, Ahmed</creator><creator>Alegezy, Mohamed</creator><creator>Elhadidy, Tamer</creator><creator>Hewidy, Asem A.</creator><creator>Zaghloul, Hossam</creator><creator>Neamatallah, Mustafa Ahmed Mohamed</creator><creator>Raafat, Douaa</creator><creator>El‐Emshaty, Wafaa M.</creator><creator>Abo El Kheir, Nermin Y.</creator><creator>El‐Bendary, Mahmoud</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5602-0989</orcidid></search><sort><creationdate>202105</creationdate><title>Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19</title><author>Elalfy, Hatem ; Besheer, Tarek ; El‐Mesery, Ahmed ; El‐Gilany, Abdel‐Hady ; Soliman, Mahmoud Abdel‐Aziz ; Alhawarey, Ahmed ; Alegezy, Mohamed ; Elhadidy, Tamer ; Hewidy, Asem A. ; Zaghloul, Hossam ; Neamatallah, Mustafa Ahmed Mohamed ; Raafat, Douaa ; El‐Emshaty, Wafaa M. ; Abo El Kheir, Nermin Y. ; El‐Bendary, Mahmoud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5370-faed8821c4ce47c597ebd5f2d29beceebe4c6444582e9e08401e334de83e0abd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antimetabolites - administration & dosage</topic><topic>Antimetabolites - therapeutic use</topic><topic>Antiparasitic Agents - administration & dosage</topic><topic>Antiparasitic Agents - therapeutic use</topic><topic>antiviral</topic><topic>Antiviral drugs</topic><topic>COVID-19</topic><topic>COVID-19 - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Ivermectin</topic><topic>Ivermectin - administration & dosage</topic><topic>Ivermectin - therapeutic use</topic><topic>Male</topic><topic>mild cases</topic><topic>Nasopharynx</topic><topic>Nitro Compounds - administration & dosage</topic><topic>Nitro Compounds - therapeutic use</topic><topic>Polymerase chain reaction</topic><topic>Ribavirin</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Thiazoles - administration & dosage</topic><topic>Thiazoles - therapeutic use</topic><topic>Trace Elements - administration & dosage</topic><topic>Trace Elements - therapeutic use</topic><topic>Virology</topic><topic>Zinc</topic><topic>Zinc - administration & dosage</topic><topic>Zinc - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elalfy, Hatem</creatorcontrib><creatorcontrib>Besheer, Tarek</creatorcontrib><creatorcontrib>El‐Mesery, Ahmed</creatorcontrib><creatorcontrib>El‐Gilany, Abdel‐Hady</creatorcontrib><creatorcontrib>Soliman, Mahmoud Abdel‐Aziz</creatorcontrib><creatorcontrib>Alhawarey, Ahmed</creatorcontrib><creatorcontrib>Alegezy, Mohamed</creatorcontrib><creatorcontrib>Elhadidy, Tamer</creatorcontrib><creatorcontrib>Hewidy, Asem A.</creatorcontrib><creatorcontrib>Zaghloul, Hossam</creatorcontrib><creatorcontrib>Neamatallah, Mustafa Ahmed Mohamed</creatorcontrib><creatorcontrib>Raafat, Douaa</creatorcontrib><creatorcontrib>El‐Emshaty, Wafaa M.</creatorcontrib><creatorcontrib>Abo El Kheir, Nermin Y.</creatorcontrib><creatorcontrib>El‐Bendary, Mahmoud</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elalfy, Hatem</au><au>Besheer, Tarek</au><au>El‐Mesery, Ahmed</au><au>El‐Gilany, Abdel‐Hady</au><au>Soliman, Mahmoud Abdel‐Aziz</au><au>Alhawarey, Ahmed</au><au>Alegezy, Mohamed</au><au>Elhadidy, Tamer</au><au>Hewidy, Asem A.</au><au>Zaghloul, Hossam</au><au>Neamatallah, Mustafa Ahmed Mohamed</au><au>Raafat, Douaa</au><au>El‐Emshaty, Wafaa M.</au><au>Abo El Kheir, Nermin Y.</au><au>El‐Bendary, Mahmoud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2021-05</date><risdate>2021</risdate><volume>93</volume><issue>5</issue><spage>3176</spage><epage>3183</epage><pages>3176-3183</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non‐randomized controlled trial included 62 patients on the triple combination treatment versus 51 age‐ and sex‐matched patients on routine supportive treatment. all of them confirmed cases by positive reverse‐transcription polymerase chain reaction of a nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% on the 7th day and 13.7% and 73.1% on the 15th day in the supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates on the 15th day are 13.7% and 88.7% in the supportive treatment and combined antiviral groups, respectively. This trial concluded by stating that the combined use of nitazoxanide, ribavirin, and ivermectin plus zinc supplement effectively cleared the SARS‐COV2 from the nasopharynx in a shorter time than symptomatic therapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33590901</pmid><doi>10.1002/jmv.26880</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5602-0989</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2021-05, Vol.93 (5), p.3176-3183 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8014583 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Antimetabolites - administration & dosage Antimetabolites - therapeutic use Antiparasitic Agents - administration & dosage Antiparasitic Agents - therapeutic use antiviral Antiviral drugs COVID-19 COVID-19 - drug therapy Female Humans Ivermectin Ivermectin - administration & dosage Ivermectin - therapeutic use Male mild cases Nasopharynx Nitro Compounds - administration & dosage Nitro Compounds - therapeutic use Polymerase chain reaction Ribavirin Ribavirin - administration & dosage Ribavirin - therapeutic use SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Thiazoles - administration & dosage Thiazoles - therapeutic use Trace Elements - administration & dosage Trace Elements - therapeutic use Virology Zinc Zinc - administration & dosage Zinc - therapeutic use |
| title | Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T11%3A02%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20a%20combination%20of%20nitazoxanide,%20ribavirin,%20and%20ivermectin%20plus%20zinc%20supplement%20(MANS.NRIZ%20study)%20on%20the%20clearance%20of%20mild%20COVID%E2%80%9019&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Elalfy,%20Hatem&rft.date=2021-05&rft.volume=93&rft.issue=5&rft.spage=3176&rft.epage=3183&rft.pages=3176-3183&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.26880&rft_dat=%3Cproquest_pubme%3E2509224528%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2509224528&rft_id=info:pmid/33590901&rfr_iscdi=true |